SLC5A2 and type 2 diabetes mellitus: In a recent prospective study in patients with HFpEF and T2DM, the use of the SGLT2 inhibitor empagliflozin for 6 months was associated with a significant reduction in LA volume, improvement in LA reservoir strain, and restoration of atrial reserve compared to the control (an enhancement of LASr increase during exercise) [41].